A clinical trial to measure the cytotoxic activity of lymphocytes increased by dasatinib treatment

A clinical trial to measure the cytotoxic activity of lymphocytes increased by dasatinib treatment - Clinical trial to measure the cytotoxic activity of lymphocytes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006501

Enrollment

Registered

2011-10-08

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic phase chronic myeloid leukemia

Interventions

patients who have already been administered with dasatinib.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic Myeloid Leukemia in chronic phase

Exclusion criteria

Exclusion criteria: Patients who have not been administered with dasatinib

Design outcomes

Primary

Measure	Time frame
Cytotoxic activity of lymphocytes during the treatment with dasatinib (chromium release assay).	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026